Introduction
Risk model | Year of publication | Recruitment period | Recruitment region | Cohort size: development/validation (n) | Procedure characteristics | Discrimination performance (c-indices in validation cohort) |
---|---|---|---|---|---|---|
1999/2003 | 1995 | Europe | 13,302/1479 | Cardiac surgery | 0.76 | |
ES II [9] | 2012 | 2010 | Worldwide, predominantly Europe | 16,828/5553 | Cardiac surgery | 0.81 |
STS PROM [10] | 2009 | 2002–2006 | US | 65,855/43,904 | Cardiac valve surgery | 0.80 |
FRANCE-2 [15] | 2014 | 2010–2011 | France + Monaco | 2552/1281 | TAVR (TF 73.4%, TA 17.8%, other 8.8%) | 0.59 |
OBSERVANT [14] | 2014 | 2010–2012 | Italy | 1256/622 | TAVR | 0.71 |
GAVS-II [16] | 2017 | 2011–2012 | Germany | 9027/9027 | 55% surgical AVR, 45% TAVR | 0.74 |
Methods
Study population and data collection
Statistics
Results
Patient population
Procedural characteristics across the TAVR era
Year | Age, years | LogES I | Patient count, n (%) | New gen. device, n (%) | TF/TA TAVR, n/n (% TF) | Procedure duration, min | Contrast volume, ml | 30-Day mortality, n (%) |
---|---|---|---|---|---|---|---|---|
2008 | 84.5 ± 4.6 | 31.7 ± 17.6 | 17 (0.6) | 0 (0) | 17/0 (100) | 59.1 ± 24.0 | 186.3 ± 45.8 | 1 (5.9) |
2009 | 79.1 ± 6.7 | 27.5 ± 18.1 | 44 (1.5) | 0 (0) | 43/1 (97.7) | 75.9 ± 29.1 | 217.1 ± 76.8 | 5 (11.4) |
2010 | 82.5 ± 5.7 | 26.4 ± 14.5 | 78 (2.6) | 0 (0) | 60/18 (76.9) | 82.6 ± 46.1 | 192.1 ± 80.9 | 5 (6.4) |
2011 | 80.9 ± 6.3 | 23.2 ± 14.1 | 188 (6.4) | 0 (0) | 156/32 (83.0) | 85.3 ± 39.0 | 166.9 ± 75.1 | 11 (5.9) |
2012 | 81.1 ± 6.1 | 22.6 ± 14.2 | 118 (4.0) | 0 (0) | 88/30 (74.6) | 88.6 ± 30.7 | 145.3 ± 88.6 | 9 (7.6) |
2013 | 81.5 ± 6.1 | 22.5 ± 16.2 | 212 (7.2) | 15 (7.1) | 187/25 (88.2) | 76.6 ± 27.0 | 128.7 ± 27.0 | 9 (4.2) |
2014 | 80.7 ± 6.0 | 21.0 ± 15.0 | 297 (10.1) | 125 (42.1) | 252/45 (84.8) | 78.2 ± 31.4 | 143.7 ± 60.2 | 13 (4.4) |
2015 | 80.7 ± 5.9 | 26.0 ± 17.9 | 361 (12.3) | 318 (88.1) | 323/38 (89.5) | 96.9 ± 43.9 | 138.7 ± 49.8 | 14 (3.9) |
2016 | 80.4 ± 6.0 | 24.6 ± 15.8 | 466 (15.8) | 461 (98.9) | 406/60 (87.1) | 87.2 ± 35.2 | 121.7 ± 39.3 | 12 (2.6) |
2017 | 81.0 ± 6.3 | 23.7 ± 16.1 | 627 (21.3) | 627 (100) | 579/48 (92.3) | 71.5 ± 32.9 | 119.9 ± 46.5 | 21 (3.4) |
2018 | 80.7 ± 6.1 | 21.0 ± 15.0 | 538 (18.3) | 538 (100) | 514/24 (95.5) | 64.9 ± 27.4 | 106.1 ± 46.1 | 8 (1.5) |
Overall | 80.9 ± 6.1 | 23.4 ± 15.9 | 2946 (100) | 2084 (70.7) | 2625/321 (89.1) | 78.7 ± 35.5 | 130.3 ± 56.0 | 108 (3.7) |
Clinical outcomes
Risk model performance for the prediction of 30-day mortality
Model discrimination
(A) Model discrimination: ROC analysis | (B) Model calibration: prediction of 30-day mortality risk | |||||
---|---|---|---|---|---|---|
Risk model | All patients (n = 2946) | TF TAVR (n = 2625) | TA TAVR (n = 321) | All patients (n = 2946) | TF TAVR (n = 2625) | TA TAVR (n = 321) |
0.63 (0.58–0.68) | 0.61 (0.55–0.67) | 0.67 (0.56–0.78) | 23.4 ± 15.9 (1.1–95.0) | 22.8 ± 15.7* (1.1–95.0) | 28.0 ± 16.9* (2.5–88.4) | |
ES II [9] | 0.65 (0.60–0.70) | 0.64 (0.58–0.70) | 0.67 (0.55–0.79) | 7.5 ± 7.4 (0.5–78.1) | 7.3 ± 7.2* (0.5–78.1) | 9.3 ± 8.8* (1.0–56.1) |
STS PROM [10] | 0.67 (0.62–0.72) | 0.66 (0.60–0.72) | 0.66 (0.57–0.76) | 6.2 ± 5.7 (0.5–69.3) | 6.1 ± 5.6* (0.6–69.3) | 7.5 ± 6.7* (0.6–58.1) |
FRANCE-2 [15] | 0.66 (0.60–0.71) | 0.63 (0.57–0.69) | 0.67 (0.55–0.79) | 9.2 ± 6.8 (4.0–62.0) | 8.3 ± 5.6* (4.0–55.0) | 16.3 ± 10.7* (6.8–62.0) |
OBSERVANT [14] | 0.60 (0.55–0.66) | 0.60 (0.54–0.67) | 0.58 (0.47–0.68) | 5.8 ± 5.0 (1.8–58.7) | 5.7 ± 5.0 (1.8–58.7) | 6.2 ± 4.9 (1.8–33.2) |
GAVS-II [16] | 0.63 (0.58–0.69) | 0.62 (0.56–0.69) | 0.67 (0.56–0.78) | 9.4 ± 9.6 (1.0–89.8) | 9.2 ± 9.1 (0.9–89.8) | 10.9 ± 12.4 (1.1–80.8) |
Risk model | 2008–2010 (n = 139) | 2011–2013 (n = 518) | 2014–2016 (n = 1124) | 2017–2018 (n = 1165) | Old-generation TAVR device (n = 862) | New-generation TAVR device (n = 2084) | Overall (n = 2946) |
---|---|---|---|---|---|---|---|
0.67 (0.50–0.85) | 0.59 (0.48–0.70) | 0.68 (0.59–0.77) | 0.57 (0.47–0.68) | 0.63 (0.55–0.71) | 0.63 (0.56–0.71) | 0.63 (0.58–0.68) | |
ES II [9] | 0.65 (0.46–0.83) | 0.57 (0.48–0.67) | 0.70 (0.61–0.78) | 0.65 (0.55–0.74) | 0.63 (0.56–0.71) | 0.66 (0.59–0.73) | 0.65 (0.60–0.70) |
STS PROM [10] | 0.53 (0.32–0.74) | 0.64 (0.56–0.73) | 0.67 (0.58–0.76) | 0.64 (0.54–0.74) | 0.63 (0.56–0.70) | 0.65 (0.57–0.72) | 0.67 (0.62–0.72) |
FRANCE-2 [15] | 0.63 (0.49–0.76) | 0.63 (0.51–0.74) | 0.66 (0.57–0.75) | 0.66 (0.57–0.76) | 0.61 (0.53–0.69) | 0.68 (0.61–0.76) | 0.66 (0.60–0.71) |
OBSERVANT [14] | 0.61 (0.41–0.82) | 0.53 (0.41–0.65) | 0.68 (0.60–0.76) | 0.57 (0.47–0.68 | 0.57 (0.49–0.66) | 0.63 (0.56–0.70) | 0.60 (0.55–0.66) |
GAVS-II [16] | 0.58 (0.37–0.79) | 0.54 (0.42–0.66) | 0.68 (0.60–0.77) | 0.66 (0.57–0.76) | 0.59 (0.50–0.68) | 0.67 (0.60–0.74) | 0.63 (0.58–0.69) |